Southborough-based clinical research organization Veristat has acquired a New Jersey CRO, Instat Clinical Research, adding new abilities to transform data to its portfolio.
Instat’s expertise is in data and study result analysis, according to a Thursday press release from Veristat.
“As biotherapeutics continue to evolve, so does biometrics, the unequivocal underpinning of clinical research,” CEO and Co-founder of Instat Kyle McBride said in the press release. “Instat possesses the ideal mix of talent, technical acumen, and technology solutions to keep pace with this change and bring statistical understanding across the clinical development lifecycle.”
Instat will bring experience in supporting over 100 sponsor-led clinical studies, authoring over 150 statistical analysis plans, and participating in over 30 regulatory submissions, according to the press release. Financial terms of the acquisition were not disclosed.
“The addition of Instat’s seasoned talent will further strengthen our ability to help clients bring their drugs and biologics to market faster,” said Veristat CEO Patrick Flanagan in the press release.
In 2022, Veristat made the Inc. 5000, a national list of the fastest growing companies from New York-based Inc. Magazine.
